Evaluation of Harm Associated with High Dose-Range Clinical Decision Support Overrides in the Intensive Care Unit

Adrian Wong, Christine Rehr, Diane L. Seger, Mary G. Amato, Patrick E. Beeler, Sarah P. Slight, Adam Wright and David W. Bates ()
Additional contact information
Adrian Wong: MCPHS University
Christine Rehr: Brigham and Women’s Hospital
Diane L. Seger: Brigham and Women’s Hospital
Mary G. Amato: MCPHS University
Patrick E. Beeler: Brigham and Women’s Hospital
Sarah P. Slight: Brigham and Women’s Hospital
Adam Wright: Brigham and Women’s Hospital
David W. Bates: Brigham and Women’s Hospital

Drug Safety, 2019, vol. 42, issue 4, No 9, 573-579

Abstract: Abstract Introduction Medication-related clinical decision support (CDS) alerts have been shown to be effective at reducing adverse drug events (ADEs). However, these alerts are frequently overridden, with limited data linking these overrides to harm. Dose-range checking alerts are a type of CDS alert that could have a significant impact on morbidity and mortality, especially in the intensive care unit (ICU) setting. Methods We performed a single-center, prospective, observational study of adult ICUs from September 2016 to April 2017. Targeted overridden alerts were triggered when doses greater than or equal to 5% over the maximum dose were prescribed. The primary outcome was the appropriateness of the override, determined by two independent reviewers, using pre-specified criteria formulated by a multidisciplinary group. Overrides which resulted in medication administration were then evaluated for ADEs by chart review. Results The override rate of high dose-range alerts in the ICU was 93.0% (total n = 1525) during the study period. A total of 1418 overridden alerts from 755 unique patients were evaluated for appropriateness (appropriateness rate 88.8%). The most common medication associated with high dose-range alerts was insulin regular infusion (n = 262, 18.5%). The rates of ADEs for the appropriately and inappropriately overridden alerts per 100 overridden alerts were 1.3 and 5.0, respectively (p

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0756-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:4:d:10.1007_s40264-018-0756-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0756-x

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().